These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 8724545

  • 1. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
    Martinelli G, Testoni N, Zuffa E, Visani G, Zinzani PL, Zaccaria A, Farabegoli P, Arpinati M, Amabile M, Tura S.
    Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
    [Abstract] [Full Text] [Related]

  • 2. FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report.
    Visani G, Tosi P, Zinzani PL, Manfroi S, Zaccaria A, Testoni N, Lemoli RM, Rosti G, Pelliconi S, Tura S.
    Br J Haematol; 1994 Feb; 86(2):394-6. PubMed ID: 7515268
    [Abstract] [Full Text] [Related]

  • 3. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).
    Tedeschi A, Montillo M, Ferrara F, Nosari A, Mele G, Copia C, Leoni P, Morra E.
    Eur J Haematol; 2000 Mar; 64(3):182-7. PubMed ID: 10997884
    [Abstract] [Full Text] [Related]

  • 4. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
    Katagiri T, Miyazawa K, Uchida Y, Hayashi S, Iwama H, Shyohji N, Kawakubo K, Shimamoto T, Inatomi Y, Kuriyama Y, Yaguchi M, Nehashi Y, Ohyashiki K, Toyama K.
    Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
    [Abstract] [Full Text] [Related]

  • 5. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
    Fleischhack G, Hasan C, Graf N, Mann G, Bode U.
    Br J Haematol; 1998 Aug; 102(3):647-55. PubMed ID: 9722289
    [Abstract] [Full Text] [Related]

  • 6. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, Ganser A, Hertenstein B.
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [Abstract] [Full Text] [Related]

  • 7. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios MB, Beran M, Deisseroth A.
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-alpha.
    Ambrosetti A, Krampera M, Veneri D, Meneghini V, Aprili F, Martinelli G, Pizzolo G, Perona G.
    Int J Clin Lab Res; 1994 Mar; 24(1):58-9. PubMed ID: 8180425
    [Abstract] [Full Text] [Related]

  • 10. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G, Graf N, Hasan C, Ackermann M, Breu H, Zernikow B, Bode U.
    Klin Padiatr; 1996 Mar; 208(4):229-35. PubMed ID: 8926688
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
    Bolaman Z, Köseoğlu M, Ayyildiz O, Kadiköylü G, Sönmez HM, Demir S, Müftüoğlu E.
    Haematologia (Budap); 2002 Mar; 32(1):49-57. PubMed ID: 12243555
    [Abstract] [Full Text] [Related]

  • 13. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N, Sarper N, Devecioğlu O, Anak S, Eryilmaz E, Can M, Yenilmez H, Ağaoğlu L, Gedikoğlu G.
    Turk J Pediatr; 2000 Mar; 42(3):198-204. PubMed ID: 11105617
    [Abstract] [Full Text] [Related]

  • 14. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M.
    Haematologica; 1996 Mar; 81(6):513-20. PubMed ID: 9009438
    [Abstract] [Full Text] [Related]

  • 15. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
    Carlo-Stella C, Regazzi E, Andrizzi C, Savoldo B, Garau D, Montefusco E, Vignetti M, Mandelli F, Rizzoli V, Meloni G.
    Haematologica; 1997 Mar; 82(3):291-6. PubMed ID: 9234574
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Experience with fludarabine treatment and review of the literature].
    Telek B, Rejtó L, Kiss A, Batár P, Reményi G, Rák K, Udvardy M.
    Orv Hetil; 2002 Jun 16; 143(24):1459-65. PubMed ID: 12138643
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.